2026 Biomedical Pitch Competition Successfully Concludes in Boston, Highlighting the Rapid Rise of Global Biotech Innovation
The 2026 Biomedical Pitch Competition successfully concluded on May 24, 2026, in Boston, marking another major milestone for one of the fastest-growing international biomedical innovation platforms connecting North America and Asia-Pacific healthcare ecosystems. Co-organized by Boston Capital Investment Club (BCIC) and Hong Kong Science and Technology Parks Corporation (HKSTP), this year's event brought together leading biotech innovators, venture capital investors, pharmaceutical executives, scientists, legal experts, CROs, CDMOs, and global healthcare industry leaders for two days of high-level exchange, company presentations, strategic networking, and cross-border collaboration. The live-streamed final event attracted over 20,000 online viewers globally, highlighting the growing international influence of the competition and the rapid rise of cross-border biotech innovation.
Figure 1: Participants, judges, speakers, sponsors, and organizers gathered at the 2026 Biomedical Pitch Competition in Boston, bringing together global leaders across biotechnology, venture capital, healthcare innovation, and translational medicine.
Following the strong momentum of previous years, the 2026 competition continued to expand in both scale and influence. Approximately 170 biotechnology companies globally, primarily from the United States and China, participated in this year's selection process, with 17 companies advancing to the final pitch competition held in Boston. Most finalist companies were in preclinical or clinical-stage development, reflecting the event's continued focus on translational medicine, commercialization, and globally scalable healthcare innovation.
Held at Fish & Richardson P.C. in Boston's Seaport District, the competition showcased an exceptional concentration of cutting-edge biomedical technologies spanning programmable RNA therapeutics, in vivo CAR-T engineering, gene therapy, immunometabolism, AI-driven drug discovery, molecular glue therapeutics, precision oncology, regenerative medicine, organoid-enabled translational platforms, and advanced drug delivery technologies. The increasing maturity of the participating companies highlighted the accelerating convergence of biotechnology innovation, artificial intelligence, and precision medicine.
BCIC, one of the most active international healthcare innovation communities connecting biotech entrepreneurs and global investors, continues to play an increasingly important role in fostering cross-border innovation and commercialization. As a Massachusetts-registered nonprofit organization serving nearly 10,000 professionals across venture capital, finance, healthcare, and technology industries, BCIC has spent years building a global ecosystem connecting startups, pharmaceutical companies, investors, incubators, and research institutions. Since launching its biomedical pitch competition platform in 2022, BCIC has helped participating companies secure significant visibility, strategic partnerships, and financing opportunities across international markets, with award-winning companies collectively securing over $300 million in funding.
The event opened with welcoming remarks from Min Yi, President of BCIC, followed by a keynote address from Dr. Weng-Li Yoon, Associate Director (Therapeutics), Life and Health Technology at HKSTP. Dr. Yoon shared insights into Hong Kong's rapidly evolving biotechnology ecosystem and discussed HKSTP's expanding role in supporting translational medicine, clinical development, and global healthcare innovation. As one of Asia's leading biotechnology hubs, HKSTP continues to accelerate commercialization through funding initiatives, innovation infrastructure, clinical translation support, and international strategic partnerships.
Several major technology themes emerged throughout this year's competition. RNA therapeutics and programmable RNA engineering represented one of the strongest trends across participating companies, with multiple startups presenting innovations involving circular RNA, mRNA-LNP delivery, oligonucleotide therapeutics, and RNA-guided immune engineering. AI-enabled therapeutic discovery also remained a dominant focus, with companies increasingly integrating machine learning, computational biology, and generative design into drug discovery pipelines.
In addition, next-generation immunotherapy approaches continued to attract significant investor and industry attention. Multiple finalist companies presented innovative strategies involving in vivo CAR-T programming, immune metabolism modulation, bispecific immune engagers, and molecular glue technologies designed to target historically "undruggable" disease pathways. Several companies also showcased highly differentiated translational platforms focused on fibrosis, metabolic diseases, neurodegeneration, ophthalmology, regenerative medicine, and organoid-enabled disease modeling.
Figure 2. Judges of the 2026 Biomedical Pitch Competition, representing leading venture capital firms, pharmaceutical companies, innovation organizations, and healthcare investment institutions across the global biotechnology ecosystem.
Figure 3. Judges, finalist teams, investors, and organizers gathered during the 2026 Biomedical Pitch Competition, highlighting the collaborative global ecosystem driving next-generation biomedical innovation.
The finalist companies included Chengdu Huitai Biomedicine, GenAns Biotechnology, Meta Pharmaceuticals, EuHearing, Suzhou Innotech Medtech, Stick Therapeutics, PACDNA, Concarlo Therapeutics, MolAIcule, Pilatus Biosciences, NovaSpira BioTherapeutics, Wink Biotherapeutics, Kernal Bio, Othelium Therapeutics, DeepNephro, Diapin Therapeutics, Hyivy Health, and additional roadshow-stage companies including Byterna Therapeutics, Accendatech US, Alteron Therapeutics, and Intertwined Biosciences.
The competition judges evaluated participating companies based on scientific innovation, translational potential, clinical impact, market opportunity, commercialization readiness, and investment attractiveness. This year's winning companies demonstrated exceptional scientific rigor, strong execution capabilities, and highly differentiated approaches to addressing major unmet medical needs.
Figure 4. Finalists and Award Winners of the 2026 Biomedical Pitch Competition.
First Place — Wink Biotherapeutics
First Place at the 2026 Biomedical Pitch Competition was awarded to Wink Biotherapeutics for its pioneering targeted RNA therapeutics platform aimed at developing potentially curative treatments for diabetes. The company is advancing modified RNA technologies designed to precisely reprogram cellular function while minimizing off-target effects, representing a highly innovative approach in next-generation metabolic disease therapeutics. Judges were particularly impressed by the company's strong translational vision, differentiated platform strategy, and the significant clinical and commercial potential of its programmable RNA-based therapeutic approach.
Figure 5. Dr. Weng-Li Yoon, CEO of Wink Biotherapeutics, and Min Yi during the award presentation ceremony at the 2026 Biomedical Pitch Competition.
Second Place — Stick Therapeutics & Diapin Therapeutics
Two companies were awarded Second Place at the 2026 Biomedical Pitch Competition: Stick Therapeutics and Diapin Therapeutics, both recognized for their highly innovative therapeutic platforms and strong translational potential.
Stick Therapeutics presented a BioAI-enabled molecular glue discovery platform that combines high-throughput protein engineering with AI-driven therapeutic design to reprogram cellular systems and identify novel small-molecule therapeutics. The judges highlighted the company's differentiated platform approach and its potential to unlock previously inaccessible biological targets through next-generation molecular glue technologies.
Diapin Therapeutics was recognized for its development of novel therapeutics targeting cardiovascular and metabolic diseases. The company's pipeline includes DT678, an improved antiplatelet therapy, and DT109, a therapeutic candidate for metabolic diseases. Judges praised the company's strong clinical relevance, clear commercialization strategy, and the significant market opportunity associated with next-generation cardiometabolic therapeutics.
Figure 6. Dr. Weng-Li Yoon, CEO of Diapin Biotherapeutics, and Min Yi during the award presentation ceremony at the 2026 Biomedical Pitch Competition.
Third Place — Concarlo Therapeutics, Meta Pharmaceuticals & Pilatus Biosciences
Three companies received Third Place honors: Concarlo Therapeutics, Meta Pharmaceuticals (HK) Limited, and Pilatus Biosciences.
Concarlo Therapeutics was recognized for its first-in-class molecular glue platform targeting intrinsically disordered proteins (IDPs) in oncology. Its lead program, Conc-142, focuses on overcoming CDK4/6 resistance through stabilization of tumor-suppressive p27 complexes, while the company's broader Prox-Glue platform aims to unlock historically "undruggable" oncology targets such as p53 and MYC.
Meta Pharmaceuticals (HK) Limited was honored for its innovative immunometabolism platform developing next-generation autoimmune therapeutics. The company's lead oral LDHA inhibitor demonstrated strong preclinical efficacy across inflammatory disease models, positioning the company at the forefront of immune metabolism–based therapeutics.
Pilatus Biosciences received recognition for its pioneering immunometabolic oncology platform focused on overcoming resistance to cancer immunotherapy. Its lead candidate, PLT012, a humanized anti-CD36 monoclonal antibody, has demonstrated strong preclinical efficacy and received FDA Fast Track and Orphan Drug Designations, highlighting its significant translational and clinical potential.
Figure 7. Dr. Weng-Li Yoon, CEO of Pilatus Biotherapeutics, and Min Yi during the award presentation ceremony at the 2026 Biomedical Pitch Competition.
Innovation Awards
Innovation Awards were also presented to Chengdu Huitai Biomedicine, EuHearing, Kernal Bio, Hyivy Health, NovaSpira BioTherapeutics, DeepNephro, Othelium Therapeutics, Suzhou Innotech Medtech, PACDNA, and MolAIcule in recognition of their highly innovative contributions to next-generation biotechnology and translational medicine.
Figure 8. Dr. Weng-Li Yoon, Min Yi and partial innovation winner teams.
The event also highlighted the growing globalization of biomedical innovation and investment. Through the collaboration between BCIC and HKSTP, the competition created a valuable international platform connecting entrepreneurs, pharmaceutical companies, CROs, CDMOs, venture investors, incubators, and academic innovators across North America and Asia.
Day 2 Forum and Networking — Bridging the Gap: From Lab to Market in a Global Ecosystem
On May 24, BCIC continued the program with the "Day 2 Forum and Networking" seminar under the theme "Bridging the Gap: From Lab to Market in a Global Ecosystem." The half-day seminar focused on the critical challenges and opportunities involved in translating biomedical innovation into globally scalable businesses and clinical products.
The Day 2 forum opened with remarks from Min Yi, President of BCIC, followed by a keynote presentation from Dr. Weng-Li Yoon of HKSTP titled "Hong Kong as Asia's Emerging Biotech Hub," highlighting Hong Kong's rapidly expanding role in biotechnology innovation, clinical translation, and international healthcare investment. Peng Lin, Partner at Fish & Richardson P.C., also delivered welcome remarks on behalf of the venue sponsor, emphasizing the growing importance of intellectual property strategy and international legal infrastructure in supporting emerging biotech companies.
Figure 9. Min Yi, President of BCIC, delivered opening remarks at the 2026 Biomedical Pitch Competition in Boston.
Figure 10. Dr. Weng-Li Yoon of HKSTP presented on Hong Kong's growing role as an emerging global biotechnology and innovation hub.
Figure 11. Peng Lin, Partner at Fish & Richardson P.C., delivered a keynote presentation on intellectual property and innovation in the global biotech ecosystem.
One of the major highlights of the seminar was the panel discussion titled "The Multi-Dimensional Launchpad," which brought together leaders from venture capital, biotechnology, legal, business development, and global innovation ecosystems to discuss the key factors driving successful biomedical commercialization.
Panelists included:
- Dr. Weng-Li Yoon, Associate Director, HKSTP
- Peng Lin, Partner, Fish & Richardson P.C.
- Hyelim Cho, VP and Head of Strategy, Actithera
- Kate Zhang, Venture Partner, Tailwinds (NLVC)
- Baolin (John) Wu, Executive Director of Technical Business Development
- Han Zhang, Managing Director, BCIC
Figure 12. Panelists from biotechnology, venture capital, intellectual property, and business development sectors participated in the Day 2 Forum discussion on global biomedical innovation and commercialization at the 2026 Biomedical Pitch Competition.
Discussion topics included global biotech investment trends, translational medicine, regulatory strategy, AI-enabled healthcare innovation, cross-border commercialization, venture financing, and the evolving role of accelerators and strategic partnerships in bringing breakthrough therapies from laboratory research into global markets.
The evening networking reception and VIP dinner also featured remarks from representatives of Fish & Richardson P.C., Porton Pharma Solutions, and Shanghai InnoStar, all of whom emphasized the growing importance of international collaboration in accelerating biotechnology innovation, clinical translation, and global commercialization.
The 2026 Biomedical Pitch Competition was supported by an outstanding network of sponsors, judges, innovation organizations, and media partners including Fish & Richardson P.C., Porton Pharma Solutions, Shanghai InnoStar, PanaCRO, Simcere Pharmaceutical Group, Fenwick, and many leading venture capital and healthcare organizations across the United States and Asia-Pacific regions.
As BCIC continues to expand its international healthcare innovation platform, the organization remains committed to fostering collaboration among scientists, entrepreneurs, investors, and industry leaders to accelerate the translation of breakthrough biomedical discoveries into transformative therapies for patients worldwide.
More Photos from the Event
Acknowledgment to Sponsors and Partners
BCIC and HKSTP would like to extend sincere appreciation to all sponsors, strategic partners, judges, speakers, and supporting organizations whose generous support and collaboration made the 2026 Biomedical Pitch Competition and Day 2 Forum possible.
Special thanks to our sponsoring and partner organizations, including Fish & Richardson P.C., Porton Pharma Solutions, Shanghai InnoStar, PanaCRO, Simcere Pharmaceutical Group, Fenwick, Tailwinds (NLVC), and many additional venture capital firms, healthcare organizations, CROs, CDMOs, and innovation partners across the United States and Asia-Pacific regions.
Their continued commitment to advancing biotechnology innovation, translational medicine, entrepreneurship, and global healthcare collaboration has played a critical role in strengthening the international biomedical ecosystem connecting academia, industry, investors, and entrepreneurs. We deeply appreciate their contributions to fostering the next generation of breakthrough therapies and transformative healthcare technologies worldwide.
Special Appreciation to Judges and Investment Partners
BCIC and HKSTP would also like to express sincere gratitude to the distinguished judges, venture capital leaders, pharmaceutical executives, and industry experts who contributed their time, expertise, and insights to support the 2026 Biomedical Pitch Competition.
We especially thank representatives and judges from Chugai Venture Fund, Lyfe Capital, Eli Lilly, PagodaTree Partners, K2VC, Pacific 8 Ventures, Northern Light Venture Capital (NLVC), TCGX, and HKSTP for their valuable participation in evaluating finalist companies and supporting the growth of next-generation biomedical innovation.
Their deep industry knowledge, investment perspectives, scientific expertise, and commitment to translational medicine provided tremendous value to participating startups and further strengthened the competition's role as a global platform for biotech entrepreneurship and cross-border collaboration.
We highly appreciate their continued support in advancing innovation, commercialization, and international partnership within the global healthcare ecosystem.
Special Thanks to Our Volunteers
BCIC would like to express sincere appreciation to all volunteers whose dedication, professionalism, and hard work contributed to the success of the 2026 Biomedical Pitch Competition and Day 2 Forum.
Volunteer Team: Min Yi, Lucia Liu, Xiao Niu, Na An, Lipin Ji, Yang Han, Han Zhang, Linda Liao, Nicole Ning, Hang Lu, Chao Suo, Bo Wang, Xiangpeng Dai, Xiang Liu, Yulin Xiao, Dongyi Zhao, Jihe Liu, Irene Zhao, Anna Fu, Joanna Yan, Peter Pan, Ziming He, Alice Li, Yingzhong Li, Daniel Luo, Kunxiang Luo, Yubin Li, Wenyan Cai, Shi Jin, Yuzhen Yu, Guoling Zhou, Tao Lin, Chloe Bu, Shiyuan Zhou, Sophia Lee, Jena Chow, Tony Tuo Liu, Yitong Wang, Xiangming Meng, Zhidan Tu, Holly Yang, Minqian Huang, Jiawei Li, Siran Luo, Xinhao Lin, Shuo Huang, Zijian Han, Yixin Hu, Shanshan Zheng, Xue Feng, Howard Feng.
Their support in event coordination, registration, guest reception, logistics, photography, and networking activities played an essential role in creating a successful, collaborative, and internationally connected biotech event.
